🔗 Share this article

Given that America proceeds with historic adjustments to its vaccine recommendations, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, a US-based sports physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus vaccines in the pandemic and has concentrated on potential fatalities after COVID-19 vaccination in her short position at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Immunization Schedule

Public health authorities were set to reveal radical revisions to the childhood vaccination calendar in December, bringing the US with the Danish vaccine program, according to reports – a significant shift that would put the US out of step with a large portion of the world with no evidence for public health gain. This reveal has been delayed until the coming year.

In place of Vinay Prasad, Høeg is scheduled to present at the event. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the office this calendar year.

A New Direction at the Agency

This interim role may indicate a closer partnership between the drug and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it points to a renewed priority upon dismantling already-approved vaccines at the FDA.

The new acting director has often pushed for discontinuing certain childhood shot schedules in the US to become more similar to Denmark's approach, a nation with comprehensive healthcare and a citizenry roughly the population of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccination policy – traditionally the purview of Dr. Prasad, head of the FDA’s vaccine center – instead of medication approval.

Doubts Over Expertise

Dr. Høeg has little discernible track record in pharmaceutical research, regulation or leadership, which has been standard for previous directors of the biologics center. She has served at the FDA as a top consultant to the agency head and the vaccine center since March.

“She appears not to have the necessary background” for running the drug-regulation department, stated a neurologist and psychiatrist. “She’s never run a clinical trial. She is not versed in managing a major agency. She is not an expert in drug approvals.”

Previous commissioners of CBER would “understand legal statutes and the underlying principles of medication creation”, noted Janet Woodcock. “Frankly, she lacks the sort of resume that prior appointees who ran the center have had.”

The drug center has an enormous workload at the FDA, the former commissioner stated.

“The public just focuses on the new drug program, but the generic drug division clears numerous off-brand pharmaceuticals. There is also a biologic copycat branch, OTC medication office and more, and each of these need to be looked after,” she explained. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant administrative aspect to the role, which manages over 5,000 personnel. “It’s a massive management job, if you execute it properly,” she said.

Official Statement and Controversial Initiatives

When asked about inquiries about Dr. Høeg's fitness for the role and whether this assignment signifies greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “inquiries rely on flawed assumptions”.

“This background aligns with the functions of her job,” the representative explained, citing the months Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a controversial rapid therapy clearance system that apparently concerned her predecessors. “How are these therapies being selected for this expedited pathway? Who makes the choices?” Dr. Howard said. “There’s a lot of secrecy occurring at the FDA right now.”

In general, he said, “the FDA seems to be moving towards less stringent oversight of most medications, with the exception of shots.”

Public Track Record on Immunizations

Regarding immunizations, Høeg has a more established, if problematic, history, some experts have noted. She published a study using unconfirmed volunteer-provided data to estimate the rate of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida top health official Joseph Ladapo, who was said to have altered data to imply Covid vaccinations are more dangerous than they are.

Among her “wish list” for the new administration featured altering regulations for novel immunizations and halting “non-essential” vaccines, she remarked post-election on a podcast. At the FDA, Høeg has allegedly proposed excluding young men from getting COVID-19 vaccines.

“She is an thorough dogmatist who starts off with her preconceived notions and reverse-engineers to accommodate the science in a highly deceptive, dishonest manner,” Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|